10q10k10q10k.net
IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc.IDYAEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.

Q3 2025Q3 2024Q2 2024Q1 2024Q3 2022

IDYA Q3 FY2025 Key Financial Metrics

Revenue

$207.8M

Gross Profit

N/A

Operating Profit

$108.5M

Net Profit

$119.2M

Gross Margin

N/A

Operating Margin

52.2%

Net Margin

57.4%

YoY Growth

N/A

EPS

$1.33

IDEAYA Biosciences, Inc. Q3 FY2025 Financial Summary

IDEAYA Biosciences, Inc. reported revenue of $207.8M for Q3 FY2025, with a net profit of $119.2M (up 330.1% YoY) (57.4% margin).

Key Financial Metrics

Total Revenue$207.8M
Net Profit$119.2M
Gross MarginN/A
Operating Margin52.2%
Report PeriodQ3 FY2025

IDEAYA Biosciences, Inc. Quarterly Revenue & Net Profit History

IDEAYA Biosciences, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q3 FY2025$207.8M—$119.2M57.4%
Q3 FY2024$0—$-51.8MN/A
Q2 FY2024$0—$-52.8MN/A
Q1 FY2024$0—$-39.6MN/A
Q3 FY2022$29.7M+230.9%$1.6M5.4%

Income Statement

Q3 2022Q1 2024Q2 2024Q3 2024Q3 2025
Revenue$29.7M$0$0$0$207.8M
YoY Growth230.9%N/AN/AN/AN/A

Balance Sheet

Q3 2022Q1 2024Q2 2024Q3 2024Q3 2025
Assets$410.9M$961.5M$973.7M$1.24B$1.19B
Liabilities$42.1M$26.2M$42.0M$59.5M$93.1M
Equity$368.8M$935.3M$931.7M$1.18B$1.09B

Cash Flow

Q3 2022Q1 2024Q2 2024Q3 2024Q3 2025
Operating CF$-24.2M$-43.8M$-32.9M$-49.2M$142.2M